发布求助
文献互助 智能选刊 最新文献

[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献

筛选
英文 中文
[Clinical utility of ctDNA in lymphoma]. [ctDNA在淋巴瘤中的临床应用]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1078
Chisako Iriyama
{"title":"[Clinical utility of ctDNA in lymphoma].","authors":"Chisako Iriyama","doi":"10.11406/rinketsu.66.1078","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1078","url":null,"abstract":"<p><p>Genetic analysis can provide important information regarding the diagnosis, subtype, and prognosis of lymphoma. There is a growing body of evidence on liquid biopsy using circulating tumor DNA (ctDNA) as an alternative method for genetic analysis. CtDNA is tumor cell-derived DNA that is found unbound in body fluids. CtDNA levels are related to cell proliferation, apoptosis rate, and disease type, and have been shown to correlate with systemic tumor volume. Unlike biopsy tissue-derived DNA, plasma ctDNA is derived from lymphomas across the entire body. Other advantages of ctDNA analysis are that it is less invasive and easy to repeat. It is not only useful for diagnosis and disease typing, but can also be used in prognostic prediction based on the ctDNA level and changes in ctDNA level with treatment, evaluation of minimal residual disease, monitoring for recurrence, early diagnosis of resistance, and early detection of transformation. This method shows great promise for future clinical applications.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1078-1086"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Molecular pathogenesis and management of myeloma bone disease]. 骨髓瘤骨病的分子发病机制和治疗
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1108
Hirokazu Miki
{"title":"[Molecular pathogenesis and management of myeloma bone disease].","authors":"Hirokazu Miki","doi":"10.11406/rinketsu.66.1108","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1108","url":null,"abstract":"<p><p>The advent of novel anti-multiple myeloma (MM) agents has led to dramatic improvement in patient survival. Nevertheless, the majority of patients with MM have bone lesions, and destructive bone lesions significantly reduce quality of life. Progressive destructive bone lesions develop when osteoblast differentiation from bone marrow stromal cells is inhibited and osteoclasts are activated in the bone marrow microenvironment in patients with MM. Recent research has also shed light on the functions and roles of osteocytes, which account for the majority of bone cells. Since MM cells mainly invade the red marrow, bone lesions are often found in the skull, spine, and ilium, which contain red marrow. Imaging is essential for the diagnosis of MM bone lesions, and whole-body low-dose CT, whole-body MRI, and FDG-PET/CT have demonstrated utility. Furthermore, recent advances in anti-MM drugs have improved the prognosis of MM significantly, highlighting the importance of treating and managing MM bone lesions. This review will explain the molecular pathology and management of MM bone lesions.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1108-1116"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Onco-cardiology in hematopoietic malignancies]. [造血恶性肿瘤的肿瘤-心脏病学]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1087
Shingo Yano
{"title":"[Onco-cardiology in hematopoietic malignancies].","authors":"Shingo Yano","doi":"10.11406/rinketsu.66.1087","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1087","url":null,"abstract":"<p><p>Cancer patients who develop cardiovascular complications have significantly lower survival rates due to their inability to continue appropriate cancer treatment. Onco-cardiology is an interdisciplinary area in which cardiologists and oncologists collaborate to optimize cancer treatment. The goal is to improve the prognosis and quality of life of cancer patients by ensuring that they can continue cancer treatment with appropriate cardiac management. When cardiotoxic anticancer drugs will be used, the oncologist should assess the patient's risk and cardiac function before starting treatment, and adjust treatment based on risk factors. During treatment, cardiac evaluation should be performed according to the patient's risk. Echocardiographic left ventricular ejection fraction (LVEF) is used to assess cancer treatment-related cardiac dysfunction (CTRCD), and global longitudinal strain is considered useful for anthracycline therapy. Troponin I/T and BNP/NT-proBNP are used as biomarkers of cardiac function. When a patient has reduced LVEF, a cardiologist should be consulted for treatment of CTRCD and cardioprotective therapy should be considered.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1087-1093"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Key points in the diagnosis of T-cell lymphoma in the 5th edition of the WHO Classification (2022)]. [WHO分类（2022）第5版t细胞淋巴瘤诊断要点]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1074
Hiroaki Miyoshi
{"title":"[Key points in the diagnosis of T-cell lymphoma in the 5th edition of the WHO Classification (2022)].","authors":"Hiroaki Miyoshi","doi":"10.11406/rinketsu.66.1074","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1074","url":null,"abstract":"<p><p>The diagnosis of T-cell lymphoma poses challenges compared to B-cell lymphoma, as it is difficult to conceptualize a normal cellular counterpart, and morphological identification of origin is nearly impossible. With limited specific markers, clinical information (e.g., lesion distribution, clinical course, and symptoms) is extremely important for diagnosis. The 5th edition of the WHO Classification clarified the classification for T/NK cell lymphomas. Key changes include the addition of the \"tumor-like lesion with T-cell predominance\" category. EBV-related T/NK lymphomas were also reorganized, and the classification and differential diagnosis of TFH phenotype lymphomas were refined. As many aspects of T-cell lymphomas remain unclear, pathologists and hematologists must work in close collaboration to integrate pathological findings with crucial clinical data to ensure accurate diagnosis.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1074-1077"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[CAR-T cell therapy in clinical practice]. 【CAR-T细胞疗法的临床应用】。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1222
Tomoyasu Jo
{"title":"[CAR-T cell therapy in clinical practice].","authors":"Tomoyasu Jo","doi":"10.11406/rinketsu.66.1222","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1222","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical efficacy in relapsed or refractory B-cell acute lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma. In Japan, five CAR-T products have already been approved and have rapidly achieved widespread adoption in real-world clinical practice. CAR-T therapy involves multiple complex steps, including autologous T-cell collection, manufacturing, bridging therapy, infusion, and management of adverse events, each of which requires careful optimization. Disease relapse or progression after CAR-T therapy also remains common, which makes it crucial to accumulate clinical experience and evidence on post-treatment management. This review outlines the current clinical use of CAR-T cell therapy in Japan, discusses practical aspects of treatment delivery throughout the process, and examines its role relative to other emerging therapies.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1222-1232"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Molecular pathogenesis and treatment of follicular lymphoma]. 【滤泡性淋巴瘤的分子发病机制及治疗】。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1048
Momoko Nishikori
{"title":"[Molecular pathogenesis and treatment of follicular lymphoma].","authors":"Momoko Nishikori","doi":"10.11406/rinketsu.66.1048","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1048","url":null,"abstract":"<p><p>Follicular lymphoma (FL) has a wide spectrum of clinical manifestations, ranging from cases that require little or no treatment to cases that are refractory to any treatment. In recent years, advances in DNA and RNA profiling, as well as analysis of the tumor microenvironment, have progressively increased understanding of the underlying molecular pathogenesis of FL. Early progression of disease following immunochemotherapy includes histologic transformation to a more aggressive phenotype, which is associated with poor survival outcomes. Recent advances beyond conventional immunochemotherapy, including small molecular compounds, bispecific antibodies, and CAR-T cell therapy, have expanded therapeutic options and improved prognosis for FL patients. Research suggests that factors associated with treatment efficacy and prognosis may not be consistent across therapeutic agents. A deeper understanding of the molecular biology of FL should pave the way for optimized, individualized treatment sequences.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1048-1054"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Novel treatment strategies for polycythemia vera: focus on ropeginterferon alfa-2b]. 真性红细胞增多症的新治疗策略：关注ropeg干扰素α -2b。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.258
Keita Kirito
{"title":"[Novel treatment strategies for polycythemia vera: focus on ropeginterferon alfa-2b].","authors":"Keita Kirito","doi":"10.11406/rinketsu.66.258","DOIUrl":"https://doi.org/10.11406/rinketsu.66.258","url":null,"abstract":"<p><p>The current main treatment goal of polycythemia vera (PV) is preventing thromboembolic and hemorrhagic complications. However, these therapeutic strategies cannot delay progression of PV. Therefore, there is an unmet need for next-generation therapeutic strategies to slow disease progression and improve survival in patients with PV. One of the most promising agents for modifying the disease course of myeloproliferative neoplasms is interferon alpha, which has been used to treat PV since the 1980s. Notably, it achieved cytogenetic or molecular responses in some patients. However, conventional interferon was not widely used due to its high incidence of adverse events and poor tolerance. Ropeginterferon alfa-2b (ropeg) is a unique, site-selective polyethylene glycol-conjugated form of recombinant interferon alpha. A phase 1/2 study of ropeg for PV patients showed low toxicity and improved tolerability, along with significant molecular response. A phase 3 randomized study (PROUD-PV/CONTINUATION-PV) revealed that treatment with ropeg continuously decreased the JAK2V617F allele burden compared to hydroxyurea and improved event-free survival (with events defined as thromboembolic events, disease progression, or death). A phase 2 study in Japanese patients with PV further confirmed the efficacy of ropeg.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 4","pages":"258-266"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Successful intensive treatment for severe fever with thrombocytopenia syndrome complicated by virus-associated hemophagocytic syndrome in a very elderly patient]. [一例高龄重症发热伴血小板减少综合征合并病毒相关噬血细胞综合征的强化治疗成功]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.233
Riichiro Ikeda, Yu Kochi, Takuya Nunomura, Kenjiro Hino, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Yuta Katayama
{"title":"[Successful intensive treatment for severe fever with thrombocytopenia syndrome complicated by virus-associated hemophagocytic syndrome in a very elderly patient].","authors":"Riichiro Ikeda, Yu Kochi, Takuya Nunomura, Kenjiro Hino, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Yuta Katayama","doi":"10.11406/rinketsu.66.233","DOIUrl":"https://doi.org/10.11406/rinketsu.66.233","url":null,"abstract":"<p><p>The patient was an 89-year-old man who had been doing farm work for several days. He had previously visited a doctor with complaints of fever and nausea. He was referred to our hospital after pancytopenia was confirmed. On the 7th day after onset, he was found to have consciousness disturbances, liver dysfunction, and worsening pancytopenia, which led to a diagnosis of hemophagocytic syndrome by bone marrow examination. Considering the patient's history of outdoor activities and the presence of crusts on the right lower leg, we suspected severe fever with thrombocytopenia syndrome (SFTS). Reverse transcription polymerase chain reaction of peripheral blood was positive for the SFTS virus, confirming the diagnosis. Epstein-Barr virus reactivation was also observed. Steroid pulse therapy and plasma exchange led to prompt clinical improvement and hematopoietic recovery. The patient recovered without sequelae and was discharged home. Few reports have described the use of plasma exchange and steroid therapy in severe cases of SFTS. This case illustrates that early detection and aggressive treatment for elderly patients contributes to early symptom improvement and survival.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 4","pages":"233-237"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Outcome of allogeneic hematopoietic stem cell transplantation for myelofibrosis]. [同种异体造血干细胞移植治疗骨髓纤维化的疗效]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.111
Takumi Nishikawa, Masuho Saburi, Kuniaki Maehara, Keiichi Uraisami, Hiroyuki Takata, Yasuhiko Miyazaki, Eiichi Ohtsuka
{"title":"[Outcome of allogeneic hematopoietic stem cell transplantation for myelofibrosis].","authors":"Takumi Nishikawa, Masuho Saburi, Kuniaki Maehara, Keiichi Uraisami, Hiroyuki Takata, Yasuhiko Miyazaki, Eiichi Ohtsuka","doi":"10.11406/rinketsu.66.111","DOIUrl":"10.11406/rinketsu.66.111","url":null,"abstract":"<p><p>We retrospectively reviewed outcomes of four patients (median age: 54.5 years) who received allogeneic stem cell transplantation for myelofibrosis at our hospital. Transplantation consisted of unrelated bone marrow transplantation (BMT) (n=1), related peripheral blood stem cell transplantation (PBSCT) (n=1), and haploidentical PBSCT with post-transplant cyclophosphamide (PTCy-haplo) (n=2). The conditioning regimen was fludarabine combined with busulfan 12.8 mg/kg or melphalan 140 mg/m<sup>2</sup>. All patients received a JAK2 inhibitor, which was gradually tapered and then discontinued before conditioning. The three PBSCT recipients achieved engraftment, and are alive in remission. The BMT recipient died of graft failure. PTCy-haplo, myeloablative conditioning, and JAK2 inhibitors may be useful for transplantation in patients with myelofibrosis.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 2","pages":"111-116"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Drug-induced sarcoidosis-like reaction due to dasatinib in the lung of a patient with chronic myeloid leukemia]. [1例慢性髓性白血病患者肺部达沙替尼引起的药物性结节病样反应]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.324
Takumi Kimura, Yoshimi Nabe, Hiroki Yoshino, Ryota Urushihara, Noriaki Tsuji, Yukio Kondo
{"title":"[Drug-induced sarcoidosis-like reaction due to dasatinib in the lung of a patient with chronic myeloid leukemia].","authors":"Takumi Kimura, Yoshimi Nabe, Hiroki Yoshino, Ryota Urushihara, Noriaki Tsuji, Yukio Kondo","doi":"10.11406/rinketsu.66.324","DOIUrl":"10.11406/rinketsu.66.324","url":null,"abstract":"<p><p>The patient was a 54-year-old woman with chronic myeloid leukemia. Ten months after treatment with dasatinib, she developed a cough. Imaging studies showed ground-glass patterns in the lower lung fields of both lungs, which led to suspicion of drug-induced lung injury and prompted discontinuation of dasatinib. A transbronchial lung biopsy showed epithelioid granuloma without necrosis in the alveolar region. There were no other systemic symptoms or signs to support a diagnosis of sarcoidosis. Fifteen days after withdrawal of dasatinib, both the cough and X-ray findings improved. Granulomatous tissue was detected on lung biopsy, which indicates that drug-induced sarcoidosis-like reaction (DISR) may cause interstitial lung injury as a respiratory complication of dasatinib treatment. Case reports of DISR following administration of immune checkpoint inhibitors and immunomodulatory drugs have recently become more frequent. Here we report a case of dasatinib-induced DISR with a review of the literature.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 5","pages":"324-330"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信